Boronophenylalanine uptake in C6 glioma model is dramatically increased by L-DOPA preloading

Area of Science:

• Oncology
• Radiochemistry
• Pharmacology

Background:

• Boron Neutron Capture Therapy (BNCT) effectiveness is limited by insufficient boron-10 (10B) uptake in tumor cells.
• Boronophenylalanine (BPA) is a key compound used in BNCT for delivering 10B to tumors.
• Enhancing BPA accumulation in malignant gliomas is crucial for improving BNCT outcomes.

Purpose of the Study:

• To investigate the potential of L-DOPA as an enhancer for BPA uptake in a C6 glioma model.
• To evaluate the efficacy of L-DOPA preloading on BPA accumulation in vitro and in vivo.
• To assess the safety and specificity of L-DOPA-enhanced BPA uptake in normal brain and blood.

Main Methods:

• In vitro assessment of BPA accumulation in C6 glioma cells using radiowave dielectric spectroscopy (RDS) with and without L-DOPA.
• In vivo study involving intra-carotid BPA infusion in rats with C6 glioma, with and without prior L-DOPA administration.
• Quantification of BPA concentrations in tumor tissue, normal brain, and blood samples using high-performance liquid chromatography (HPLC).

Main Results:

• L-DOPA preloading significantly increased BPA concentration in C6 glioma cells in vitro.
• In vivo, L-DOPA administration led to a substantial rise in BPA concentration within the animal model's tumor.
• No significant differences in BPA levels were observed in normal brain or blood samples between groups.

Conclusions:

• L-DOPA acts as a potent enhancer for BPA accumulation in C6 glioma models.
• The findings suggest L-DOPA's potential utility in increasing BPA delivery to malignant gliomas for BNCT.
• This approach may improve BNCT efficacy by maximizing therapeutic agent concentration within tumors while sparing healthy tissues.